Roger Laham, MDRoger Laham, MD
Office Address: BIDMC, Harvard medical School,
East Campus, SL 423C
330 Brookline Avenue, Boston, MA 02215
Home Address: 39 Kent Street #4
Brookline, MA 02445
E-Mail: rlaham@caregroup.harvard.edu
Telephone: (617) 632-9204
FAX: (617)-975-5201
Education:
1982 Baccalaureate College des Frères Sacré-Coeur
1985 B.S. American University of Beirut
1989 M.D. American University of Beirut
Postdoctoral Training:
1989-1990 Intern, Department of Medicine
Duke University Medical Center, Durham, NC
1990-1991 Junior Resident, Department of Medicine
Duke University Medical Center, Durham, NC
1991-1992 Senior Resident, Department of Medicine
Duke University Medical Center, Durham, NC
1992-1994 Clinical Fellow, Cardiovascular Division
BIH, Harvard Medical School, Boston, MA
1994-1996 Clinical Fellow, Interventional Cardiology Section
BIH, Harvard Medical School, Boston, MA
1994-1996 Fellow, Angiogenesis Research Center
Licensure and Certification:
1989, 1992,1994 Certified, Advanced Cardiac Life Support
1996, 2001 American Heart Association
1992 Diplomat, American Board of Internal Medicine
Internal Medicine
1992-present State of Massachusetts Medical License
1995 Diplomat, American Board of Internal Medicine
Cardiovascular specialty
1999 Diplomat, American Board of Internal Medicine
Interventional Cardiology
2004 Recertified, American Board of Internal Medicine
Internal Medicine
2005 Recertified, American Board of Internal Medicine
Cardiovascular specialty
Academic Appointments:
1992-1995 Clinical Fellow in Medicine
Harvard Medical School, Boston, MA
1995-1999 Instructor in Medicine
Harvard Medical School, Boston, MA
1999-2002 Assistant Professor of Medicine
Harvard Medical School, Boston, MA
2002- Associate Professor of Medicine
Harvard Medical School, Boston, MA
Hospital Appointments:
1999-present Assistant Director, Interventional Cardiology
BIDMC/Harvard Medical School, Boston, MA
1999-2001 Director, Clinical Research
Angiogenesis Research Center
BIDMC/Harvard Medical School, Boston, MA
2000-present Director, Basic Angioplasty Research
Interventional Cardiology Section
2001-present Director, Angiogenesis Research Center
BIDMC/Harvard Medical School, Boston, MA
Major Committee Assignments:
1988-1989 Member, Continuing Education Committee
American University
1995-1996 Member, Committee on Bylaws
Massachusetts Medical Society
1998-2005 Member, Committee on Clinical Investigation
BIDMC, Boston, MA
2000-2005 Delegate, Massachusetts Medical Society
2000-2002 Scientific Committee and Course Co-director, Vienna Annual Interdisciplinary scientific congress
2001-present Scientific Committee, International Congress on Coronary Artery Disease
2000-present Scientific Committee, International Coronary artery Disease Congress
2001-present International Referee, Biomedical Research Council, Singapor
2002-present National Referee, Department of Defense Research Program, Breast Cancer study section
2002-present Society of Cardiac Angiography and Interventions Credentials Committee
2003-present Reviewer for the NHLBI Program of Excellence in Gene Therapy (PEGT) National Cores
2003 Reviewer, GlaxoSmithKline fellowship Research and Development Fellowship Program
2004 Reviewer FDA intramural program
2005 Reviewer for the NHLBI study section on cell based therapy
Professional Societies:
1993 Member, Massachusetts Medical Society
1993 Member, American Medical Association
1994 Member, American College of Physician
1994 Member, American College of Cardiology
1998 Member, American Heart Association Council on Atherosclerosis,
Thrombosis, and Vascular Biology
1999 Member, Society for Cardiac Magnetic Resonance Imaging
2000 Delegate, Massachusetts Medical Society
2001 Fellow, American Heart Association Council on Atherosclerosis,
Thrombosis, and Vascular Biology
2002 Fellow of American Society for Cardiovascular Angiography and
Interventions (FSCAI)
2002 Member, American Association for Advancement of Science
2003 Fellow of the American College of Cardiology (FACC)
2005 Member, Society for Vascular Medicine and Biology
2006 Faculty, Harvard Stem Cell Institute
2006 Fellow, American Heart Association Council on Cardiovascular
Radiology and Intervention
Editorial Boards:
1998-present Associate Editor Uptodate in Medicine
1999-present Editorial Board Cardiac and Vascular
Regeneration
1998-present Editorial Board CHF Disease Management
1998-present Editorial Board Complementary Therapies in
Chronic Care
2002-present Editorial Board Catheterization and
Cardiovascular Interventions
2003-present Editorial Board Cardiovascular Radiation Medicine
1999-present Ad-hoc reviewer Circulation
1999-present Ad-hoc reviewer Journal of the American
College of Cariology
1999-present Ad-hoc reviewer Catheterization and
Cardiovascular Intervention
2000-present Ad-hoc reviewer Clinical and Experimental
Immunology
2000-present Ad-hoc reviewer American Journal of
Cardiology
2000-present Ad-hoc reviewer Cardiac and vascular
regeneration
2001-present Ad-hoc reviewer Journal of Pharmacology
and Experimental Therapy
2001-present Ad-hoc reviewer New England Journal
of Medicine
2001-present Ad-hoc reviewer American Heart Journal
2001-present Ad-hoc reviewer American Journal of
Physiology
2002-present Ad-hoc reviewer The Lancet
2002-present Ad-hoc reviewer Am. J. of Cardiovascular
Drugs
2002-present Ad-hoc reviewer Trends in Molecular
Medicine
2002-present Ad-hoc reviewer Coronary Artery Disease
2003-present Ad-hoc reviewer Current gene therapy
2003-present Ad-hoc reviewer Gene Therapy (Nature)
2003-present Ad-hoc reviewer Diabetes
2004-present Ad-hoc reviewer Gene Therapy and Molecular
Biology
2004-present Ad-hoc reviewer Circulation Research
Awards and Honors:
1982-1989 Dean's Honor List, American University of Beirut
1985 Bachelor of Sciences with High Distinction, American University
of Beirut
1987-88 Franklin Thomas Moore-Ethel Jessup Memorial Prize
American University of Beirut
1987-88 Munib Shahid Prize, American University of Beirut
1989 Doctor of Medicine with Distinction, American University of Beirut
1989 Penrose Award (for the best combination of the qualities of scholarship, character, leadership, and contribution to the University as a whole), American University of Beirut
1993-1996 Physician’s Recognition Award, American Medical Association
1994-1995 Hewlett-Packard Fellowship Award in Cardiovascular Research
1995 American College of Cardiology/Bristol-Myers Squibb Affiliate Travel Award
1996-1999 Physician’s Recognition Award, American Medical
Association
1996 The Altman Award Endowment Fund for Outstanding Talent as Clinician, Researcher, and Humanitarian Deliverer of Care, BIH, Boston, MA
1996 Pharmaceuticals Travel Award
1999 Plenary Lecture, Transcatheter Therapeutics Symposium
2001 Plenary Lecture, Vienna Interdisciplinary Symposium
2001 Plenary Lecture, Moscow Cardiology Summit
2001 Plenary Lecture, American Heart Association meeting, Rockport, Maine
2001 Plenary Lecture, Cardiac Magnetic Resonance Imaging Society Scientific Session
2001 Keynote speaker, International Congress on Coronary artery disease
2002 GCRC Award, presented at GCRC/NCRR annual meeting in Baltimore, MD
2002 Allen Ephraim Diamond Lecturer (Keynote address), Toronto
2003 Stafford Cohen development award
2005 Dean’s International Council, University of Chicago Harris School
of Policy
Patents:
2004- Methods and compositions for treating
conditions involving abnormal angiogenesis
using RTEF-1-Filed
2005- METHODS TO EXCLUDE LEFT ATRIAL APPENDAGE IN
TREATMENT OF ATRIAL FIBRILLATION-FILED
2006- DEVICES AND METHODS FOR TISSUE TRANSPLANT AND
REGENERATION-FILED
2006- DEVICES AND METHODS FOR CARDIAC
RESTRAINT AND TREATMENT OF HEART DILATION AND FAILURE
2006- DEVICES AND METHODS FOR PERCUTANEOUS VALVE REPLACEMENT
Part II: Research, Teaching, and Clinical Contributions:
A. Narrative:
Teaching: Teaching responsibility has involved mainly the supervision and instruction of nurse practitioners, medical students, housestaff, and fellows in the division of cardiology at BIDMC, and at Harvard Medical School in clinical cardiology, interventional cardiology, and clinical angiogenesis research. Teaching has involved 7 nurse practitioners, 20 medical interns and residents, and 8 medical students that are rotating through the clinical services attended, including the coronary care unit and the cardiology units. This also included lectures given to medical interns, residents, cardiology fellows and medical students about interventional cardiology and angiogenesis. The number of hours spent yearly preparing and delivering these teaching responsibilities approximates 7 hours weekly, including the yearly cardiovascular exam teaching to second year medical students.
Other teaching contributions include the instruction of physician in the U.S., Canada, and Europe in performing advanced interventional procedures including electromechanical left ventricular mapping, various Atherectomy techniques, crossing total occlusions, intramyocardial injections, distal protection, high risk interventions. I serve as a mentor to a number of trainees. I also serve on the scientific committee of several teaching courses for medical professionals nationally and internationally.
Research: Since joining the fellowship program and then the faculty rank BIDMC/Harvard Medical School, my research activities centered on translational research in vascular biology, angiogenesis, myogenesis, and new device development. These efforts have taken the form of basic research projects focused on restenosis and the endothelial responses to angiogenic growth factors, animal research projects focused on physiologic assessment of coronary angiogenesis in porcine models of myocardial ischemia and murine models of acute myocardial infarction, drug delivery research, cell based therapy, microtissue transplantation, and finally clinical trials testing efficacy of angiogenic growth factors in patients with advanced coronary disease. My research was funded by a Hewlett-Packard fellowship award (1995), a career development award program (CAP) from the General Clinical Research Center, NCRR (1997-2000 and then 2000-2002), a project I lead in a SCOR program (2000-2005), as well as industry funding. Eight of my former trainees now hold faculty rank in academic institutions in the US and abroad and every one of my trainees have had research presentations at major national meetings (AHA, ACC, TCT, etc.). My current basic research efforts are concentrated on understanding the mechanism of action of novel angiogenic cytokines in vitro (matrigel models and migration assays) and in vivo using small animal models of myocardial infarction (mouse MI model), microorgan and myotissue transplantations and cord blood transplantation. The use of the mouse MI model allows a better understanding of the steps needed for functionally significant angiogenesis by using mice lacking key genes in the angiogenic cascade (enos knockout,…) with selective expression of certain genes in the heart (transgenic models). I am assisted in this work by two postdoctoral fellows and Dr. Jian Li (Assistant Professor), who acts as an advisor on these studies. We are currently investigating the role of exercise in the development of collaterals and overexpression of FGF and VEGF and their receptors in mice models of myocardial infarction. In addition, SDF-1, Cord blood derived stem cell, APC, microorgans, myotissue, cardiac stem cells are ongoing. Large animal studies have recently focused on local delivery of angiogenic agents to the heart, but more recently, we are investigating cell based therapy and microtissue transplantation in large animal models for myocardial regeneration and myocardial ischemia. This work will be the basis of an investigator/industry sponsored IND/IDE for the investigation of cell based therapy for heart failure. I am assisted in this project by a post-doctoral fellow and a surgical resident. An upcoming project which will involve basic, preclinical, and clinical experimentation is investigating the effect of B-Natriuretic peptide on endothelial function and proliferation, coronary microvascular resistance, coronary blood flow, and epicardial tone. This is an investigator initiated, industry funded project that will investigate the hemodynamic and angiogenic effects of Natrecor, a human B-type natriuretic peptide. Since my focus is translational research, the other projects involve clinical trials of angiogenesis, myogenesis, and prevention of restenosis. I am the principal investigator on several clinical studies including new device trials and several angiogenesis trials. My research efforts have been recognized by my peers as publications in several peer-reviewed journal as well as presentations at most National and International meetings in Cardiology. I have delivered several keynote and plenary presentations and was invited to deliver the opening lecture at the International CAD meeting and I am asked to review manuscripts and grant proposals from several prestigious journals and funding agencies.
B. Research Funding:
Past: |
|
|
1994-1995 |
Hewlett-Packard Fellowship Award Program Biology of atherosclerosis |
Principal Investigator |
1997-2000 |
NIH-GCRC CAP Award, MO1-RR01032 |
Principal Investigator |
1996-1998 |
Genentech Inc. |
Co-Investigator |
1997-1998 |
Chiron Inc. |
Co-Investigator |
1997-1998 |
Genentech Inc. |
Co-Investigator |
1999-2004 |
Biosense Inc., Johnson and Johnson |
Principal Investigator |
1998-1999 |
Chiron Inc. |
Co-Investigator |
2000-2002 |
NIH-GCRC CAP Award extension, RR01032 |
Principal Investigator |
1999-2002 |
Biosense Inc., Johnson and Johnson |
Principal Investigator |
1998-2002 |
Chiron Inc. |
Principal Investigator |
2001-2003 |
Diacrin Inc. |
Principal Investigator |
2001-2002 |
Cook Interventional |
Principal Investigator |
2001-2002 |
Jomed Inc. |
Principal Investigator |
2001-2002 |
Berlex Laboratories Inc. |
Principal Investigator |
2001-2002 |
Transvascular Inc. |
Principal Investigator |
2002-2004 |
Valentis Inc. |
Principal Investigator |
2002-2004 |
Vascular Genetics Inc. |
Principal Investigator |
2002-2004 |
Scios Inc. |
Principal Investigator |
2002-2003 |
Scios Inc. |
Principal Investigator |
2000-2005 |
Project V of NIH Ischemia SCOR, HL 63609 |
Principal Investigator |
2000-2002 |
Cardiovascular Therapeutics |
Principal Investigator |
Current: |
|
|
2002-2007 |
NIH/NHLBI-1RO1HL69024-01A1 (Sellke PI). Surgical Intramyocardial Angiogenesis in a Swine Model of hypercholesterolenemia |
Co-Investigator |
2003-2006 |
Skin Microorgan role in inducing angiogenesis, BIRD Foundation |
Principal Investigator |
2004-2006 |
Preclinical assessment of the Triactive Device, Kensey nash |
Principal Investigator |
2005-2007 |
Clinical Trial of ranolazine in unstable angina, TIMI-36, Merlin study |
Principal Investigator |
2006-2008 |
Clinical trial of spinal cord stimulation for refractory angina, ANS, Dallas, TX |
National Principal Investigator |
2006-2008 |
Clinical trial of Plasmid-VEGF 165 using intramyocardial injections in patients with end stage coronary disease, Corautus Genetics, Atlanta |
Principal Investigator |
2005-2008 |
Core 64, multislice CT angiography compared to angiography for detection of CAD, Toshiba, Japan |
|
|
|
|
|
|
|
|
|
|
C. Research Activity:
1996-1998 |
Intracoronary, local delivery, and perivascular angiogenic effect of VEGF |
Co-Principal Investigator: Designed and conducted experiments in animal models |
1997-1999 |
Role of bFGF in limiting infarct size after experimental coronary ligation in mice: mechanisms and potential therapeutic benefit |
Co-Principal Investigator: Designed and conducted experiments in animal models |
1998-1999 |
Intrapericardial bFGF in a large animal model of myocardial ischemia |
Co-Principal Investigator: Designed and conducted experiments in animal models |
1999-2001 |
Tissue and myocardial distribution and retention of heparin-binding growth factors after intracoronary, intravenous, and intrapericardial delivery |
Principal Investigator: Conceived, proposed, designed, and conducted experiments in animal models |
1999-2001 |
Tissue and myocardial distribution and retention of heparin-binding growth factors after intramyocardial delivery |
Principal Investigator: Conceived, proposed, designed, and conducted experiments in animal models |
2000-2001 |
Tissue and Myocardial distribution of growth factors and gene therapy vectors after angiosense delivery |
Principal Investigator: Conceived, proposed, designed, and conducted experiments in animal models |
2001 |
Epicardial versus adenoviral delivery of VEGF121 |
Principal Investigator: Conceived, proposed, designed, and supervised experiments in animal models |
2000-2001 |
Angiogenic efficacy of aFGF in a porcine ameroid constrictor model |
Co-Principal Investigator: Conceived, proposed, designed, and supervised delivery experiments in animal models |
2001 |
Evaluation of a novel Angiojet thrombectomy device |
Principal Investigator: Conceived, proposed, designed, and supervised experiments in animal models |
2001-2002 |
Evaluation of autologous myoblast transplant for ischemic heart disease and congestive heart failure |
Principal Investigator: Conceived, proposed, designed, and supervised experiments in animal models |
2001-2002 |
Study of effect of exercise on myocardial angiogenesis and myocardial expression of angiogenic cytokines in a mouse model of myocardial infarction |
Principal Investigator: Conceived, proposed, designed, and supervised experiments in animal models |
2002- |
Study of effect of BNP (Natrecor) on endothelial cell proliferation and migration |
Principal Investigator: Conceived, proposed, designed, and supervised experiments |
2002- |
Effects of Stromal Derived Factor-1 on stem cell trafficking in mouse model |
Principal Investigator: Conceived, proposed, designed, and supervised experiments |
2002- |
Study of microvascular effects and signaling pathways of BNP (Natrecor) using isolated microvessels |
Principal Investigator: Conceived, proposed, designed, and supervised experiments |
2003- |
Study of Triactive system novel design, Kensey Nash |
Principal Investigator: Conceived, proposed, designed, and supervised experiments |
2003- |
Characterization of cord blood for angiogenesis/myogenesis as stem cells |
Principal Investigator: Conceived, proposed, designed, and supervised experiments |
2003- |
Microtissue transplantation (skin microorgans) for angiogenesis, BIRD foundation |
Principal Investigator: Conceived, proposed, designed, and supervised experiments |
2004- |
Microtissue transplantation (autologous myocardial tissue) for myogenesis |
Principal Investigator: Conceived, proposed, designed, and supervised experiments |
2004- |
Investigation of AV graft model of restenosis and failure |
Co-Investigator: assisted in development of protocol and IVUS imaging |
2004- |
Hypercholesterolenemic model of myocardial ischemia |
Co-Investigator: assisted in development and conduct of protocol |
Outcome Research:
1999- |
Use of magnetic resonance imaging in clinical angiogenesis studies |
Co-Principal Investigator: Conceived, proposed, designed, and supervised experiments in animal models |
1998-2001 |
Use of magnetic resonance imaging in clinical laser myocardial revascularization studies |
Principal Investigator: Conceived, proposed, designed, and supervised experiments |
1999-2002 |
Use of BIOSENSE NOGA mapping as an outcome measure in angiogenesis studies |
Principal Investigator: Conceived, proposed, designed, and supervised experiments |
2001- |
Outcome in no-option patients |
Principal Investigator: Conceived, proposed, designed, and supervised experiments |
2002- |
Placebo effect in Cardiovascular disease |
Principal Investigator: Conceived, proposed, designed, and supervised experiments |
Clinical trials: (Most of the current clinical trials are also listed in current funding)
1994-1996 |
Metoprolol in Dilated Cardiomyopathy Trial: Multicenter trial of metoprolol in heart failure |
Co-Investigator: Analyzed and collected data on enrolled patients |
1995-1997 |
Flolan therapy in congestive heart failure: Multicenter trial of a novel inotrope in heart failure |
Co-Investigator: recruited and enrolled patients and collected data |
1995-1997 |
Respit Trial (OPC 18790 use in congestive heart failure): Multicenter trial of a novel inotrope in heart failure |
Co-Investigator: recruited and enrolled patients and collected data |
1996-2001 |
bFGF angiogenesis trial. Single center investigator initiated trial of basic fibroblast growth factor for therapeutic angiogenesis |
Co-Principal Investigator: Helped conceive, propose, design, and conduct clinical trial experiments |
1997-1998 |
Intracoronary rhVEGF angiogenesis trial: Multicenter phase I study of vascular endothelial growth factor in patients with ischemic heart disease, |
Co-Investigator: submitted regulatory documents, recruited and enrolled patients and collected data |
1997-1999 |
Hu23F2G for AMI with primary angioplasty: Multicenter trial of a novel inflammation inhibitor in acute myocardial infarction |
Co-Investigator: submitted regulatory documents, recruited and enrolled patients and collected data |
1998-1999 |
Intravenous rhVEGF angiogenesis trial: Multicenter phase I study of vascular endothelial growth factor in patients with ischemic heart disease |
Co-Investigator: submitted regulatory documents, recruited and enrolled patients and collected data |
1998-1999 |
rFGF-2 angiogenesis study: intracoronary/intravenous/PhaseII: Multicenter phase I-II study of basic fibroblast growth factor in patients with ischemic heart disease, |
Co-Investigator: helped design study with sponsor, carried out preclinical evaluation, submitted regulatory documents, recruited and enrolled patients and collected data |
1998-2000 |
Betacath denovo and in-stent restenosis radiation study: Multicenter study of beta radiation in the prevention of restenosis |
Co-Investigator: recruited, enrolled, and followed patients |
1998-2000 |
VEGAS II study: Multicenter study of a novel thrombectomy device to remove clot from coronary and venous conduits |
Co-Investigator: recruited, enrolled, and followed patients |
1998-2000 |
SAFER study: Multicenter study of a distal occlusion device to guard against embolization and no-reflow after angioplasty |
Co-Investigator: recruited, enrolled, and followed patients |
1998-1999 |
SPORT study: Multicenter study of rotational atherectomy in coronary arteries |
Co-Investigator: recruited, enrolled, and followed patients |
1998-1999 |
AMIGO study: Multicenter study of directional coronary atherectomy in heart disease |
Co-Investigator: recruited, enrolled, and followed patients |
1998-2001 |
DIRECT study: Multicenter study of BIOSENSE-guided laser myocardial revascularization in patients with severe coronary artery disease |
Co-Principal Investigator: Helped conceive, propose, design, and conduct clinical trial |
1998-2001 |
Halt-MI study: Multicenter study of a novel inhibitor to reduce reperfusion injury after myocardial infarction |
Co-Investigator: recruited, enrolled, and followed patients |
1999-2001 |
Park-Davis Intramyocardial injection trial: Multicenter study of the intramyocardial injection of an adenoviral construct containing VEGF121 in patients with severe coronary artery disease |
Principal Investigator: Helped conceive, propose, design, and conduct clinical trial in three centers in the US |
1999-2001 |
Cutting balloon registry in patients with coronary artery disease |
Principal Investigator: Center PI with responsibility for patient enrollment and follow-up |
2001-2002 |
Target study: Comparison of Reopro and Aggrastat for PCI, |
Co-Investigator: recruited, enrolled, and followed patients |
2001- |
Subxyphoid Access of the Pericardium using a blunt tip needle, |
Principal Investigator: conceived, proposed, designed, and supervised conduct of single center clinical trial |
2001- |
Ethanol Ablation in Hypertrophic Obstructive Cardiomyopathy |
Co-Principal Investigator: conceived, proposed, designed, and supervised conduct of single center clinical trial |
2001-2002 |
ESPRIT trial: Comparison of Integrilin vs placebo in PCI |
Co-Investigator: recruited, enrolled, and followed patients |
2001- |
CARISA study to evaluate Ranolazine in patients with angina |
Principal Investigator: site PI, supervised conduct of multicenter clinical trial at BIDMC |
2001- |
Cardioseal closure device in patients with patent foramen ovale and cryptogenic stroke |
Principal Investigator: conceived, proposed, designed, and supervised conduct of single center clinical trial of an HDE device |
2001- |
Cardioseal closure device in patients with ventricular septal defect |
Principal Investigator: conceived, proposed, designed, and supervised conduct of single center clinical trial of an HDE device |
2001- |
Magnetic Resonance Imaging in Coronary Artery Disease |
Principal Investigator: conceived, proposed, designed, and supervised conduct of single center clinical trial. Obtained funding |
2001 |
Magnetic Resonance Imaging in Angiogenesis and Laser Myocardial Revascularization study |
Principal Investigator: conceived, proposed, designed, and supervised conduct of single center clinical trial. Obtained funding |
2001- |
Use of Relaxin in patients with ischemic cardiomyopathy |
Principal Investigator: conceived, proposed, designed, and supervised conduct of single center clinical trial, trial still not started |
2001- |
Magnetic Resonance Imaging in patients undergoing therapeutic Angiogenesis with adenoviral VP-16-Hypoxia Induced factor-1 |
Principal Investigator: helped conceive, propose, design, and supervise conduct of study. Obtained funding |
2001- |
Evaluation of the Cook Incorporated Logic Coronary Stent |
Principal Investigator: site PI, supervised recruiting and enrolling patients |
2001- |
Autologous myocyte cell transplantation in patients undergoing CABG |
Principal Investigator: helped conceive, propose, design, and supervise conduct of study. Carried out preclinical studies for clinical trial |
2001- |
Use of Jomed covered stent for vein graft interventions |
Principal Investigator: site PI, supervised recruiting and enrolling patients |
2002- |
Use of Paclitaxel Coated stent to prevent restenosis, Patency Study |
Principal Investigator: site PI, supervised recruiting and enrolling patients |
2002- |
Valentis Study, Plasmid based Del-1 delivery for ischemic heart disease |
Principal Investigator: helped conceive, propose, design, and supervise conduct of three center study. Obtained funding |
2002- |
VEGF-2 Myocardial Angiogenesis study (VGI) |
Principal Investigator: site PI, supervised recruiting and enrolling patients |
2002- |
FGF-4 adenoviral study for Angiogenesis |
Principal Investigator: site PI, supervised recruiting and enrolling patients |
2002- |
Effects of Natrecor on Coronary Circulation (Scios): |
Principal Investigator: helped conceive, propose, design, and supervise conduct of single center study. Obtained funding |
2002- |
Clinical study to elucidate mechanism of placebo effect |
Principal Investigator: helped conceive, propose, design, and supervise conduct of single center study. Obtained funding |
2003- |
Cooling for myocardial infarction, INNER COOL study |
Principal Investigator: site PI, supervised recruiting and enrolling patients |
2003- |
SISR study of brachytherapy vs drug eluting stents |
Co-Investigator: recruited, enrolled, and followed patients |
2003- |
Protect, anticoagulation strategy for PCI |
Co-Investigator: recruited, enrolled, and followed patients |
2004 |
Cool MI, cooling for myocardial infarction |
Co-Investigator: recruited, enrolled, and followed patients |
2004 |
MERLIN study of ranolazine in unstable angina |
Principal Investigator: site PI, supervised recruiting and enrolling patients |
2004 |
SHOCK II study in shock patients |
Co-Principal Investigator |
2005 |
Core 64, multislice CT angiography compared to angiography for detection of CAD |
Co-Principal Investigator: Site cardiology PI, supervised recruiting and enrolling patients |
2006 |
Clinical trial of Plasmid-VEGF 165 using intramyocardial injections in patients with end stage coronary disease |
Principal Investigator: site PI, supervised recruiting and enrolling patients |
2006 |
Clinical trial of spinal cord stimulation for refractory angina |
National Principal Investigator: helped conceive, propose, design, and supervise conduct of multicenter study. |
D. Report of Teaching:
1. Local Contribution:
1992-2001 |
Medicine 502M.1A |
1992-2001 |
Medicine 502M.1B |
1998-2000 |
IN709M.Jb. Patient-Doctor II |
1998-2001 |
Biosense NOGA training at BIDMC |
2000 |
IN750M.J-Patient Doctor IIIFaculty tutor |
2001 |
Cardiology fellow trainingFaculty educator |
2001 |
Medical Resident and Intern teaching in CCU and CardiologyFaculty educator |
2002 |
Nurse educational symposiumFaculty educator |
2002 |
Medical Housestaff lecture series in CCUFaculty educator |
2003 |
Medical Housestaff lecture series in CCUFaculty educator |
2003 |
Nurse practitioners and fellowsFaculty educator |
2004 |
Nurse practitioners and fellowsFaculty educator |
2004 |
Medical Housestaff lecture series in CCUFaculty educator |
2005 |
Medical Housestaff lecture series in CCUFaculty educator |
2005 |
Nurse practitioners and fellowsFaculty educator |
Local (BIDMC/HMS):
1998 |
Invited lecture, Therapeutic angiogenesis, General Clinical Research Center, Boston, MA |
1998 |
Cardiology Seminar: Therapeutic angiogenesis, outcome measures, Chiron site visit, BIDMC, Boston, MA |
1999 |
Cardiology Seminar: Harvard teaching hospitals combined interventional live course, Interventional Cardiology Meeting, Boston, MA |
1999 |
Invited Seminar on Angiogenesis; Therapeutic Angiogenesis, MR Research Meeting, BIDMC, Boston, MA |
1999 |
Angiogenesis/DMR, Joint Program in Nuclear Medicine Seminar Series at Harvard Medical School, Boston, MA |
2000 |
BIDMC Research Symposium, Angiogenesis/DMR, Boston, MA |
2000 |
BIDMC/Harvard Medical School cardiology grand rounds: Angiogenesis, Boston, MA |
2000 |
Harvard Interventional Cardiology Course, The no-option patient, Boston, MA |
2001 |
BIDMC nursing educational day, Ethanol ablation for hypertrophic cardiomyopathy, BIDMC, Boston, MA |
2002 |
Invited Speaker and Moderator, First GCRC Translational Research Series: Angiogenesis, from Bench to Bedside, BIDMC, Boston, MA |
2002 |
Speaker, Fellowship education series, Options for no-option patients, BIDMC, Boston, MA |
2003 |
Speaker, Fellowship education series, Options for no-option patients, BIDMC, Boston, MA |
2004 |
Lecturer, Coronary care Unit lecture series, 7 lectures on management of critical cardiology patients |
2004 |
Speaker, Fellowship education series, Ethanol septal ablation, BIDMC, Boston, MA |
2005 |
Lecturer, Coronary care Unit lecture series, 5 lectures on management of critical cardiology patients |
|
|
2. Regional:
1998 |
Cardiology Seminar: Massachusetts General Hospital. Clinical Angiogenesis. Boston, MA |
1999 |
Medical Grand Rounds: Alternative Revascularization, Good Samaritan Medical Center, Brockton, MA |
1999 |
Medical Grand Rounds: Glover Day conference, The No Option patient, Glover, MA, May 1999 |
2001 |
Speaker, 51st Annual American Heart Association meeting, Treatment for no-option patients, Rockport, Maine |
2001 |
Speaker, Cardiology Grand Rounds, DHMC, Dartmouth Medical School, Innovative interventional therapies, Lebanon, New Hampshire |
2001 |
Speaker, Medicine Grand Rounds, DHMC, Dartmouth Medical School, Treatment of “no-option” patients, Lebanon, New Hampshire |
2002 |
Speaker, Landmark Community education, Landmark Hospital, The future of Cardiovascular Care, Rhode Island |
2002 |
Gene therapy and cell based therapy conference: Gene Therapy for Angiogenesis, Cambridge, MA |
2002 |
Novel devices in Cardiology, Le Meridien Hotel, Boston, MA |
2004 |
Speaker, David Spodick Symposium, Worcester, MA |
2005 |
Speaker and Discussant, BioCare non-invasive imaging conference, Waltham, MA |
2005 |
Speaker, percutaneous valves for valvular heart disease, Harvard Clinical Research Institute, Boston, MA |
3. National and International contributions:
1995 |
Cardiology Seminar: New Device Interventions, Michigan State University, East Lansing, MI |
1996 |
Cardiology Seminar: Interventional Cardiology, Texas Tech University, Amarillo, TX |
1996 |
Cardiology Seminar: Vascular Biology: The Bridge Between Molecular Biology and Interventional Cardiology, Marshall’s University, Morgantown, WV |
1996 |
Cardiology teaching series: A Prospective evaluation of the outpatient initiation of antiarrhythmic therapy. American College of Cardiology, ACCEL recording |
1997 |
Cardiology Seminar: Interventional Vascular Biology, University of Maryland Medical System, Baltimore, MD |
1998 |
Cardiology Seminar, TCT XI, Biosense NOGA mapping and Biosense guided laser myocardial revascularization, National Interventional Cardiology meeting, Washington, DC |
1998 |
Cardiology Seminar: Biosense guided DMR, Cardiology Seminar, Swedish Hospital, Seattle, WA |
1999 |
Cardiology Training Course, NOGA mapping, Tips and Tricks, Ethicon J&J Training Site, Cincinnati, OH |
1999 |
Course Director: Cincinnati training in NOGA mapping, Role of NOGA mapping in Clinical Practice, Cincinnati, OH, April |
1999 |
Cardiology Seminar: NOGA summit, Cardiology meeting on intracardiac navigation technology Washington, DC |
1999 |
Invited lecture, Basic concepts in Angiogenesis, International meeting, American Society of Artificial Internal Organs Annual meeting, San Diego, CA |
1999 |
Cardiology Seminar: Magnetic Resonance Imaging as an outcome measure in laser myocardial revascularization, International Cardiology Meeting, Angiogenesis and DMR meeting, WHC, Washington DC |
1999 |
Invited lecture: Angiogenesis Update, Laser DMR: current perspectives, National Cardiology meeting, Santa Fe, Santa Fe, NM |
1999 |
invited lectures: Angiogenesis from bench to bedside, Cordis Webster educational seminar, Philadelphia, PA |
1999 |
Invited lecture: Angiogenesis: State of the science, St Michael’s Hospital, University of Toronto, Toronto, Canada |
1999 |
Invited lecture: 2nd Annual Cardiac Cath Lab Government Cardiologist Meeting, Cordis, Miami, FL |
1999 |
The Multivaried role of MRI in Cardiology: Plennary session, Transcatheter Cardiosvacular Therapeutics XI, Washington, DC |
1999 |
Biosense NOGA validation: Transcatheter Cardiosvacular Therapeutics XI, Washington, DC |
1999 |
Angiogenesis, State of the art, Cardiology Grand Rounds, Erie Medical Center, Erie, PA |
1999 |
Angiogenesis in Interventional Cardiology, 2nd Vienna Interdisciplinnary Symposium, Vienna, Austria |
1999 |
Fundamental Aspects of Angiogenesis, European Society of Hematology meeting, Paris, France |
1999 |
Drug delivery, Angiogenesis consensus meeting, Angiogenesis Foundation, Atlanta, GA |
1999 |
Magnetic Resonance imaging in heart disease Atlanta Cardiology Research Institute, Atlanta, GA |
1999 |
Frontiers of Angiogenesis, Beijing Medical University, Beijing, China |
2000 |
Transcatheter Cardiovascular Interventions, Future of Gene Therapy in Heart Failure, Intravascular and Perivascular Approaches to Angiogenesis, New Delhi, India |
2000 |
EuroCVS, Laser Myocardial Revascularization, Magnetic Resonance Imaging in Laser Myocardial Revascularization, Den Haag, The Netherland |
2000 |
Angiogenesis Consensus Meeting, MRI as an outcome measure in clinical angiogenesis studies, Anaheim, CA |
2000 |
FDA consensus meeting on Angiogenesis/DMR: Angiogenesis from Bench to Bedside, MRI as an outcome measure in angiogenesis, MD |
2000 |
St Michael’s Hospital, University of Toronto, Initiation of intramyocardial injection program, Toronto, ON |
2000 |
Hahneman University, Grand Rounds, Angiogenesis, fact or fiction, Philadelphia, PA |
2000 |
NOGA training course, NOGA mapping the Laham way, Cincinnati, OH |
2000 |
Middle East Medical Assembly, Angiogenesis/DMR: the no option patient, Beirut, Lebanon |
2000 |
Angiogenesis/DMR, A critical review of TMR, Angiogenesis using FGF, Washington, DC |
2000 |
Treatment of Ischemic Heart Disease in the Third Millennium, Angiogenesis in heart disease, Thessaloniki, Greece |
2000 |
Novel treatments in Heart Disease, Alternative revascularization, Quebec, Canada |
2000 |
Panel on angiogenesis: the future of Angiogenesis and Myocardial revascularization, Intervention 2000 meeting, Atlanta, GA |
2000 |
State of the Art Imaging: Latest advances in Gated Cardiac MRI, WEBCAST and CYBERSESSION |
2000 |
Session Chair and Gene therapy strategies for angiogenesis, 3rd International Congress on Coronary Artery Disease, Lyons, France |
2000 |
Cost effectiveness of brachytherapy, 3rd International Congress on Coronary Artery Disease Cordis Concurrent Session, Lyons, France |
2000 |
American Heart Association Scientific Session, Session moderator, New Orleans, LA |
2000 |
Session Chairman, Clinical Angiogenesis, Speaker: Clinical Angiogenesis Review, Basics of gene therapy, 3rd International Interventional cardiology and cardiac surgery meeting, Vienna, Austria |
2001 |
Speaker, Treatment of no-option patients, Kensey-Nash Advisory Board meeting, Philadelphia, PA |
2001 |
Speaker, Session Chairman, American Heart Association Scientific Conference on Therapeutic Angiogenesis and Laser Myocardial Revascularization, Delivery strategies for Angiogenesis, Direct Trial for Laser Myocardial Revascularization, Santa Fe, New Mexico |
2001 |
Speaker, American College of Cardiology, 50th Annual Scientific Session, Outcome measures in Angiogenesis, Orlando, Florida |
2001 |
Speaker and proctor, Cell based therapy for Angiogenesis, Euroinject Initiation, Copenhagen, Denmark |
2001 |
Speaker and moderator, Delivery strategies for therapeutic angiogenesis, Angiogenesis and DMR symposium, Washington, DC |
2001 |
Orlando Interventional Meeting, Live case transmission and faculty discussion, Orlando, FL |
2001 |
Speaker and moderator, TCT 2001, Optimizing Routes of Administration for Biologic Therapies in Specific Disease Syndromes, Enabling Technologies and Routes of Administration, Clinical Effectiveness of Perivascular bFGF Delivery, Angiogenesis—Current Status and Future Directions, Live case demonstration, The Physiologic Basis of the Placebo Effect In No-Option Patients, Emerging Applications of Genomics in Interventional Cardiology, Washington, DC |
2001 |
Opening Lecture, Fourth International conference on Coronary artery disease, Angiogenesis: the future. Symposium on Angiogenesis Delivery modalities in Myocardial angiogenesis. Session Moderator Angiogenesis. Prague, Czech Republic |
2001 |
Invited Speaker and Moderator, First Interdisciplinary Conference on the Non-invasive treatment of coronary artery disease. Moscow, Russian Federation |
2001 |
Invited speaker, Fifth annual scientific meeting: Angiogenesis Theory and Practice, Gene Therapy for Cardiovascular Diseases, Hong Kong, China |
2002 |
Plenary Session on Interventional Magnetic Resonance Imaging, Society of Cardiac MR Scientific Session: MR-assisted Gene Therapy, Orlando, FL |
2002 |
CRT 2002, Interventional Symposium: Delivery modalities in Cardiology, Washington, DC |
2002 |
Orthodiagnostic Expert meeting panel: Point of Care in Interventional Cardiology, Newark, NJ |
2002 |
AFMR 2002, GCRC 2002 scientific sessions: Placebo effect in end stage ischemic heart disease, Baltimore, MD |
2002 |
Speaker and moderator, TCT 2002, Optimizing Routes of Administration for Biologic Therapies in Specific Disease Syndromes, Enabling Technologies and Routes of Administration, Clinical Effectiveness of Perivascular bFGF Delivery, Angiogenesis— Update, Live case demonstration and discussion, Point Counterpoint debate: TMR, PMR: effect of sugar Pill, Intervention on totally occluded vein grafts: a challenge that should no longer be resisted, Washington, DC |
2002 |
Speaker, Plenary Session, Meeting of Lebanese association of Cardiologist and Cardiac surgeons, No option patient treatment, Conquering restenosis: Drug eluting stents and Brachytherapy, Beirut, Lebanon |
2002 |
Speaker, Medical grand rounds, Gene Therapy for Angiogenesis, Beirut, Lebanon |
2002 |
Speaker, Plenary session, Vienna Interdisciplinary symposium on cardiology and cardiac surgery, Treatment of Vein graft disease, Gene therapy for angiogenesis (replacement speaker, missed meeting),Vienna, Austria |
2002 |
Speaker, Plenary session, Cardiological Society of India meeting, Role of brachytherapy in the era of drug eluting stents, Gene therapy for angiogenesis, Cochin, India |
2003 |
Speaker and Moderator, CRT2003, Angiogenesis by perivascular delivery, Washington DC |
2003 |
Kensey Nash Scientific Advisory Board, A History of Delivery Strategies for the Heart, St Thomas, US Virgin Islands |
2003 |
Speaker and moderator, TCT2003, Washington DC |
2003 |
Speaker and moderator, Buones Aires Interventional meeting, Argentina 2003 |
2003 |
Speaker and moderator, Mexico City interventional congress, Mexico |
2003 |
Speaker and moderator, 2nd annual Bioassist meeting, Paris France |
2003 |
Speaker and moderator, 5th annual International CAD meeting, Florence, Italy |
2003 |
Speaker and moderator, 3rd annual International meeting on atherosclerosis, Washington DC |
2003 |
Speaker, Society of Cardiac angiography and intervention, Boston, MA |
2003 |
Speaker, American College of Cardiology annual meeting, Chicago, IL |
2004 |
Speaker, Millenium seminar, Dallas, Texas |
2004 |
Speaker, CCU rounds, BIDMC, Boston |
2004 |
Speaker, Angiogenesis and Myogenesis symposium, Washington DC |
2004 |
Speaker, University of Oklahoma Cardiology Grand rounds, Oklahoma city, OK |
2004 |
Speaker, Oklahoma Cardiovascular Association meeting, Oklahoma city, OK |
2004 |
Speaker, Cardiology Grand Rounds, Aiforce Hospital, San Antonio, TX |
2004 |
Speaker, Cardiology Grand Rounds University of Texas at San Antonio VA, San Antonio, TX |
2004 |
Speaker, Cordis Headquarters, Miami, Florida |
2004 |
Speaker, Cardiology Grand Rounds, Dayton Cardiolgy center, Dayton, OH |
2004 |
Speaker, Cardiology Grand Rounds, Mt Sinai Hospital, Dayton, OH |
2004 |
Invited speaker, Imaging of stem cell therapy, American heart Association Scientific session, New Orleans, LA |
2005 |
Speaker, Minneapolis Heart Institute Cardiology Grand Rounds, Minneapolis, Minnesota |
2005 |
Speaker, Methodist Hospital Grand Rounds, Minneapolis, Minnesota |
2005 |
Invited speaker, meet the experts, American College of cardiology, Orlando, Florida |
2005 |
Keynote address, Connecticut regional meeting, Hartford, CT: treatment of no option patients |
2005 |
Keynote address, 24th meeting of society of Toxicologic Pathology, Washington DC |
2005 |
ANS advisory board meeting, spinal cord stimulation, design of a clinical trial |
2005 |
Percutaneous treatment of valve disease, Dubai International heart meeting, Dubai, UAE |
2005 |
International academy of Cardiology: Myogenesis, Vancouver, BC, Session chair and speaker |
2005 |
ACLS course CMC, Beirut, lebanon |
2005 |
Myogenesis: beyond cell therapy, 6th International CAD meeting, Istanbul, Turkey |
2005 |
TCT 2005, Ethanol Ablation for hypertrophic cardiomyopathy, SFA revascularization, Myotissue transplantation, Washington DC |
2005 |
American heart Association Scientific Sesssions, Cord Blood between ES cells and adult stem cells, cellular transdifferentiation, future of Cardiac surgery, Dallas, Tx |
2006 |
Live Russia transmission, Treatment of no option patients, Harvard Medical School |
2006 |
CRT 2006, Cord blood transplantation for myocardial repair, myotissue transplantation for myocardial regeneration, Washington DC |
| 2006 | TCT 2006, Speaker, Moderator, and Discussant, Washington DC |
2006 |
Harvard Medical International Dubai City Medical meeting, Cardi |